Malignant Melanoma Stage IV
15
2
2
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
20.0%
3 terminated out of 15 trials
72.7%
-13.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients with Metastatic Malignant Melanoma Treated with Targeted Therapies or Immunotherapy ( MALT )
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
The IRMI-FMT Trial
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
Combined Modality Treatment for Patients With Stage IV Melanoma